On July 11, Alnylam Pharmaceuticals fell 5.08% in regular trading, trading at $296.89 USD/share, with Turnover of $334 million.
Within the Biotechnology sector where Alnylam Pharmaceuticals belongs, the overall sector showed broad weakness. Among individual stocks, AbbVie down 1.47%, Ionis Pharmaceuticals down 7.84%, Moderna down 11.17%, Gilead Sciences down 3.64%, BridgeBio Pharma down 4.11%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)